0001209191-23-048845.txt : 20230908
0001209191-23-048845.hdr.sgml : 20230908
20230908190027
ACCESSION NUMBER: 0001209191-23-048845
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230907
FILED AS OF DATE: 20230908
DATE AS OF CHANGE: 20230908
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SCHEGERIN MARC
CENTRAL INDEX KEY: 0001773184
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38940
FILM NUMBER: 231246413
MAIL ADDRESS:
STREET 1: ARQULE INC
STREET 2: 1 WALL ST FL6
CITY: BURLINGTON
STATE: MA
ZIP: 01803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Morphic Holding, Inc.
CENTRAL INDEX KEY: 0001679363
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473878772
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE A2
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 9787296480
MAIL ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE A2
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Morphic Holding, LLC
DATE OF NAME CHANGE: 20160712
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-09-07
0
0001679363
Morphic Holding, Inc.
MORF
0001773184
SCHEGERIN MARC
C/O MORPHIC HOLDING, INC.
35 GATEHOUSE DRIVE, A2
WALTHAM
MA
02451
0
1
0
0
CFO and COO
0
Common Stock
2023-09-07
4
M
0
20000
15.00
A
44136
D
Common Stock
2023-09-07
4
S
0
6691
53.2004
D
37445
D
Common Stock
2023-09-07
4
S
0
13309
54.9166
D
24136
D
Stock Option (right to buy Common Stock)
15.00
2023-09-07
4
M
0
20000
0.00
D
2030-04-05
Common Stock
20000
57268
D
Includes 396 shares of Common Stock acquired under the Issuer's employee stock purchase plan on February 28, 2022.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person dated June 28, 2022.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.73 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.19 to $55.10 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option vested as to 25% of the total shares on April 6, 2021, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on April 6, 2024, subject to the reporting person's provision of service to the Issuer on each vesting date.
/s/ Robert Farrell as attorney-in-fact for Marc Schegerin
2023-09-08